Business Context and Reporting Period
Company: OraSure Technologies, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 9, 2003
Event: The Company announced the receipt of U.S. Food and Drug Administration (FDA) approval for its OraQuick® Rapid HIV-1 Antibody Test for use with venipuncture whole blood samples.
Key Financial Metrics
This filing is a Current Report regarding a regulatory event and does not contain financial statements. The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material change reported is the expansion of the approved sample types for the OraQuick® Rapid HIV-1 Antibody Test to include venipuncture whole blood samples, in addition to previously approved methods.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates by reference a press release dated September 9, 2003, detailing the FDA approval.
Risks and Contingencies: No specific risks or contingencies are detailed within the text of this 8-K filing beyond the standard regulatory context of the approval.
Investor Verification Checklist
- Verify the specific clinical performance data associated with the new venipuncture whole blood sample approval.
- Review the attached Exhibit 99 (Press Release) for details on commercial availability and market impact.
- Confirm if this approval alters the Company's competitive landscape or reimbursement strategies.
- Check subsequent filings for financial impact projections related to this regulatory milestone.